---
title: "Private Label vs Custom Cosmetic Formulation"
description: "Private label or custom cosmetic formulation? Compare actual offers on customization, evidence access, responsibilities and manufacturing transfer, with a decision matrix."
image: "https://cosmetic-labs.com/wp-content/uploads/private-label-vs-custom-formulation-1200x1200-1.webp"
---
# Private Label vs Custom Cosmetic Formulation

> Private label or custom cosmetic formulation? Compare actual offers on customization, evidence access, responsibilities and manufacturing transfer, with a decision matrix.

Source: https://cosmetic-labs.com/articles/private-label-vs-custom-formulation
Created: 2026-10-23T17:32:24+00:00
Modified: 2026-10-25T09:07:38+00:00
Author: Emilie SCHOL

Private Label vs Custom Cosmetic Formulation | Cosmetic Labs

## **Key takeaways**

Start with the product requirements, then ask each supplier what its route name includes and excludes.

An existing formula is useful only if the offered configuration, claims and evidence fit the intended project.

Custom development is not evidence of formula ownership, exclusivity or an unrestricted right to move production.

Keep critical documentation and transfer questions as explicit holds. Do not trade them away for an attractive route description.

Go with an existing-formula offer when the product as offered, the changes the supplier allows and the evidence available all fit your brief. Consider custom formulation when a defined requirement needs development work the existing offer cannot cover. Neither route wins by default, so compare the written scope rather than the service name. In this guide, “private label” means starting from a formula the supplier already has and “custom formulation” means developing against your brief. Suppliers use both terms loosely, so confirm what any offer includes. The comparison covers customization, documentation, responsibilities and transfer, and the [cosmetic product development roadmap](https://cosmetic-labs.com/cosmetic-product-development-guide) shows where this decision sits in the wider launch process.

## Translate route terminology into a written scope
Here, **an existing-formula offer** starts from an identified formulation the supplier already sells. **Custom formulation** starts with development work against your brief. Real offers often mix the two, and the contract decides what you actually get.

When a quotation says *private label*, *white label* or *custom*, ask what the term covers in that offer. Is it branding changes only, selected product changes or development against new requirements? Which work is already done, and which deliverables still have to be commissioned?

*Contract manufacturing* raises the same question and says nothing on its own about where the formula comes from. Ask whether the proposal covers development, manufacture to a supplied specification, filling, packaging procurement or a combination, and who performs and reviews each part.

One written request makes offers comparable even when their names differ: “Identify the starting formula, permitted changes, evidence included, excluded work and decisions still required.” Then use the [supplier due-diligence checklist](https://cosmetic-labs.com/how-to-choose-a-cosmetic-lab) to verify the companies and sites behind each offer.

## Compare actual offers with this decision matrix
Use the matrix to ask both suppliers the same questions, not to score route labels.

DecisionExisting-formula offerCustom-development offerEvidence to requestFit to the briefConsider if the identified formula already meets the essential requirementsConsider if unmet requirements need defined developmentRequirement-by-requirement response and open questionsPermitted changesEstablish which changes the offer actually allowsEstablish the development boundaries and revision scopeWritten inclusions, exclusions and change processDifferentiationIdentify which product or brand differences the offer can supportDefine the difference the development must achieveAcceptance criteria and any relevant contractual commitmentsDocumentationCheck existing evidence against the intended product and packIdentify evidence to be generated and its recipientsReport register, applicability review and access arrangementsResponsibilitiesIdentify tasks not covered by the supplied formulationIdentify owners across development, assessment and manufactureDeliverables and accountable-party mapResourcesPlan the work needed to evaluate and adopt the offerPlan the work needed to commission and review developmentProject plan, dependencies and itemized scopeProduction portabilityAsk what manufacturing and transfer access is availableAsk the same questions, and do not infer portability from developmentRelevant rights, specifications and transfer deliverablesProceed or holdProceed only as far as the confirmed fit and evidence justifyProceed only as far as the agreed scope and evidence justifyDecision owner, unresolved holds and clearance conditionsAn unresolved essential requirement should block the decision whatever your overall preference. A better sample or a slicker presentation does not answer a missing documentation question. The [development stage-gate roadmap](https://cosmetic-labs.com/cosmetic-product-development-guide#stage-gates) separates permission to explore a route from approval to manufacture or launch.

## Which offer supports the customization you actually need?
The right starting point depends on the requirement, not on whether “custom” sounds more distinctive. Write down the outcome you need before deciding how much development to buy.

For an existing-formula offer, ask which essential requirements the identified version meets unchanged. Then separate branding and artwork changes from changes to the formula, pack, intended use or claims. Any change of the second kind needs a technical reviewer to say what it means for the existing evidence.

For custom development, define the difference the work must deliver. A brief that asks for “something unique” gives nobody a basis for accepting a prototype. Specify the sensory target, intended use, pack assumptions and ranked requirements, and leave formulation choices to the formulator.

In short: prefer the existing offer if its confirmed scope meets the brief. Commission development when an essential requirement is unmet and justifies the work. If neither candidate can show a workable route to that requirement, keep looking.

Customization does not create exclusivity. If restricting access to the formula or product matters, negotiate it as a separate contract term. The [cosmetic formula ownership and transfer questions](https://cosmetic-labs.com/cosmetic-formula-ownership/) cover the rights in detail.

## Compare usable documentation, not promises that it is “covered”
What matters is evidence that applies to your product, not evidence that merely exists. Ask what each report identifies, which configuration it covers and who can access it for the assessment you need.

For an existing-formula offer, ask for a register of available evidence and its scope. Check whether your formula version, packaging, use and proposed claims are covered or need further review. Evidence for an earlier product does not automatically carry over to a new configuration.

For custom development, find out what evidence the project will generate, who commissions it, who interprets it and when it will be available. Agree what happens if a result is inconclusive or unfavorable. Calling a project “custom” does not give you a testing or assessment plan.

For an EU launch, [Articles 10 and 11 of the Cosmetics Regulation](https://publications.europa.eu/resource/cellar/9382f98e-9b27-11f1-b25c-01aa75ed71a1.0001.02/DOC_1#art_10) (consolidated version of 18 May 2026) distinguish the safety assessment and safety report from the wider Product Information File. The responsible person’s obligations attach to the actual product, whatever the supplier calls its service.

For a US launch, the [FDA’s MoCRA overview](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra) sets out safety-substantiation responsibilities and record-keeping. These are market obligations that neither route label satisfies on its own.

The offer to favor is the one with a workable, documented evidence path for your project. A supplier can coordinate that path, but run the [due-diligence questions](https://cosmetic-labs.com/how-to-choose-a-cosmetic-lab) before accepting a general promise that “compliance is included.”

## Compare responsibilities and resource needs without assuming costs
Neither route removes the need for someone on the brand side to own decisions. Compare the work your team must do, the specialists it must involve and what the supplier actually includes.

For an existing-formula offer, list the adoption tasks: assessing fit, settling the pack, reviewing claims and artwork, obtaining applicable evidence and confirming manufacturing arrangements. Mark anything excluded rather than assuming it comes with the formula.

For custom development, list the development tasks alongside those same launch tasks. Decide who writes the brief, consolidates sample feedback, approves revisions and declares the product ready for the next evidence gate. If your team cannot fill a role, find out how it will be covered.

Ask both suppliers for an itemized scope with assumptions and dependencies. Compare included revisions, third-party work, report access, component sourcing and decision points before reading anything into the totals. Cost, lead time and minimum orders vary by supplier and project, so neither route has a built-in advantage on any of them.

Choose the offer whose work and dependencies your team can actually manage. If your preferred route leaves an essential role unassigned, close that gap before committing.

## Treat manufacturing transfer as a separate requirement
If you might ever need to move production, raise it before choosing an offer. Paying for custom development does not by itself give you formula ownership or unrestricted manufacturing rights, and an existing-formula offer does not necessarily rule out a transfer arrangement.

Ask both suppliers what they can release, and to whom: formula details, raw-material and finished-product specifications, manufacturing instructions and supporting records. Ask what help they would give a receiving manufacturer, under the actual agreement and its confidentiality terms.

Keep access for safety assessment separate from access for manufacturing. A safety assessor may see confidential technical information without that settling what a future manufacturer could receive or do with it.

Have counsel review the rights and restrictions in the proposed agreement, because ownership, enforceability and freedom to manufacture depend on its terms and jurisdiction. If portability is essential, treat any unresolved access or transfer term as a hold on the commitment it affects, whichever route you choose. The [supplier checklist](https://cosmetic-labs.com/how-to-choose-a-cosmetic-lab) helps you test practical capability as well as promised documents.

## Record the route decision with its remaining unknowns
A route decision should say what can happen next. It should not suggest the product is ready to launch. Here is how a record might read when one offer looks promising but neither is fully evidenced:

**Project:** moisturizer M01, brief B02, decision R01.
**Essential requirements:** works with proposed pump pack P01, and portability is assessed before any manufacturing commitment.
**Offer E:** existing formula F10, no formula change proposed. Whether existing evidence covers P01 is unconfirmed.
**Offer C:** development against B02. Evidence deliverables and transfer terms unconfirmed. No ownership or schedule advantage assumed.
**Decision:** continue assessing E’s fit and ask both suppliers for written clarification. Do not commission C just because it is labeled custom.
**Owners:** packaging supplier provides P01 specifications. E’s technical lead identifies relevant evidence and gaps. C’s project lead defines deliverables. Brand procurement lead and counsel clarify transfer terms for both offers.
**Hold:** no development spend or manufacturing order authorized.
**Reopen when:** fit, evidence gaps, scoped work and transfer position are documented. If E cannot meet an essential requirement, assess C against a specific, revised development task.
**Decision owner:** brand product lead, with technical and legal questions referred to the appropriate reviewers.

The record leaves the real questions open instead of inventing a winner by scoring unknowns.

## Choose the next commitment, not an abstract winner
Choose an existing-formula offer when its confirmed scope fits your requirements. Choose defined development when a specific unmet requirement justifies it and the proposed work is realistic. Put either route on hold while essential evidence, responsibilities or rights remain unresolved. Take the resulting scope into [supplier due diligence](https://cosmetic-labs.com/how-to-choose-a-cosmetic-lab), then use the [development roadmap](https://cosmetic-labs.com/cosmetic-product-development-guide) to plan the next gate.

Spotted an error or an outdated requirement? [Contact Cosmetic Labs](https://cosmetic-labs.com/platform/contact) with the passage and a supporting source. Cosmetic Labs runs a [directory connecting beauty brands with cosmetic labs](https://cosmetic-labs.com/platform). Publisher details are in the [legal notice](https://cosmetic-labs.com/compliance/notice).

Author: Emilie SCHOL    Founder of Cosmetic Labs, the B2B platform connecting cosmetic brands with labs, CROs and raw-material suppliers. Former Business Development Manager at QIMA Life Sciences (cosmetic & pharma CRO). Based in Toulouse, France.

Updated on

October 25, 2026

First posted on

October 23, 2026
Sources
## Sources and references
References supporting this page are listed below. Source access dates and supported claims are recorded in the evidence notes where available.
[Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast)](https://publications.europa.eu/resource/cellar/9382f98e-9b27-11f1-b25c-01aa75ed71a1.0001.02/DOC_1)

URL

[https://publications.europa.eu/resource/cellar/9382f98e-9b27-11f1-b25c-01aa75ed71a1.0001.02/DOC_1](https://publications.europa.eu/resource/cellar/9382f98e-9b27-11f1-b25c-01aa75ed71a1.0001.02/DOC_1)

Publisher

Publications Office of the European Union

Date

May 18, 2026
[Modernization of Cosmetics Regulation Act of 2022 (MoCRA)](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra)

URL

[https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra)

Publisher

US Food and Drug Administration
[IP Assignment and Licensing](https://www.wipo.int/en/web/business/assignment-licensing)

URL

[https://www.wipo.int/en/web/business/assignment-licensing](https://www.wipo.int/en/web/business/assignment-licensing)

Publisher

World Intellectual Property Organization
[Commission Implementing Decision of 25 November 2013 on Guidelines on Annex I to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (2013/674/EU)](https://publications.europa.eu/resource/cellar/82ff9107-5686-11e3-a8cb-01aa75ed71a1.0006.03/DOC_1)

URL

[https://publications.europa.eu/resource/cellar/82ff9107-5686-11e3-a8cb-01aa75ed71a1.0006.03/DOC_1](https://publications.europa.eu/resource/cellar/82ff9107-5686-11e3-a8cb-01aa75ed71a1.0006.03/DOC_1)

Publisher

Publications Office of the European Union

Date

November 26, 2013
FAQ
## Frequently asked questions

### What if the offer starts with an existing base but includes changes?

Describe both parts of the work. Identify the starting version, proposed changes and scope of new development, then ask which evidence needs review. There is no need to force the offer into one box if the written scope is clearer. Record any report that no longer applies to the revised formula or pack before approving further work.

### Can the route decision change after supplier discussions?

Yes, as a planning decision. Record why the original offer no longer meets the brief and what the alternative would need to deliver. Reconcile scope, evidence, responsibilities and contractual questions before authorizing new work. Do not assume existing commitments disappear when the project label changes, and identify who can approve the revised scope.

### Does private label remove the need for safety documentation?

No. An existing formula still needs evidence applicable to the product you place on the market. For the EU, the safety assessment and PIF duties remain with the responsible person. In the US, MoCRA requires adequate safety-substantiation records. Ask which documents the offer includes, who can access them and whether they cover your proposed configuration.

### Does custom formulation include exclusivity or production portability?

Only if the agreement grants the relevant rights and access. WIPO distinguishes ownership transfers from licences and recognises different licensing scopes. A custom-development label settles none of those terms. Have counsel review permitted manufacture and disclosure, then ask the receiving technical team whether the promised documents and assistance would support an actual production transfer.

### Can I reuse existing reports after changing the packaging?

Reuse depends on whether the evidence still applies to the new product-pack combination. EU safety-report guidance asks for stability evidence relevant to the marketed product and addresses packaging effects. Have a qualified reviewer identify the changes, assess each report and specify any further work. Do not treat a report register or an unchanged formula as automatic coverage.

Continue with

[Google](https://cosmetic-labs.com/?lean_auth=start&provider=google&redirect_to=https://cosmetic-labs.com/&error_return=https://cosmetic-labs.com/articles/private-label-vs-custom-formulation)
[LinkedIn](https://cosmetic-labs.com/?lean_auth=start&provider=linkedin&redirect_to=https://cosmetic-labs.com/&error_return=https://cosmetic-labs.com/articles/private-label-vs-custom-formulation)

© 2026 Cosmetic Labs. All rights reserved.

---

## Site identity

- Organization: Cosmetic Labs
- Description: Cosmetic Labs is a directory and a platform to meet all your cosmetic product development needs. From sourcing raw material to finding the best CRO for your needs.
- Website: https://cosmetic-labs.com

```json
[{"@type":"Article","headline":"Private Label vs Custom Cosmetic Formulation","url":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation","mainEntityOfPage":{"@id":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation#webpage"},"image":{"@type":"ImageObject","url":"https:\/\/cosmetic-labs.com\/wp-content\/uploads\/private-label-vs-custom-formulation-1200x1200-1-1024x1024.webp","width":1024,"height":1024,"caption":"A hand selects a packaged cosmetic beside a beaker of cream being stirred on a digital scale."},"datePublished":"2026-10-23T17:32:24+00:00","dateModified":"2026-10-25T09:07:38+00:00","author":{"@type":"Person","name":"Emilie SCHOL","url":"https:\/\/cosmetic-labs.com\/members\/39984"},"inLanguage":"en-US","publisher":{"@id":"https:\/\/cosmetic-labs.com#organization"},"citation":[{"@type":"CreativeWork","name":"Regulation (EC) No 1223\/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast)","url":"https:\/\/publications.europa.eu\/resource\/cellar\/9382f98e-9b27-11f1-b25c-01aa75ed71a1.0001.02\/DOC_1","datePublished":"2026-05-18","publisher":{"@type":"Organization","name":"Publications Office of the European Union"}},{"@type":"CreativeWork","name":"Modernization of Cosmetics Regulation Act of 2022 (MoCRA)","url":"https:\/\/www.fda.gov\/cosmetics\/cosmetics-laws-regulations\/modernization-cosmetics-regulation-act-2022-mocra","publisher":{"@type":"Organization","name":"US Food and Drug Administration"}},{"@type":"CreativeWork","name":"IP Assignment and Licensing","url":"https:\/\/www.wipo.int\/en\/web\/business\/assignment-licensing","publisher":{"@type":"Organization","name":"World Intellectual Property Organization"}},{"@type":"CreativeWork","name":"Commission Implementing Decision of 25 November 2013 on Guidelines on Annex I to Regulation (EC) No 1223\/2009 of the European Parliament and of the Council on cosmetic products (2013\/674\/EU)","url":"https:\/\/publications.europa.eu\/resource\/cellar\/82ff9107-5686-11e3-a8cb-01aa75ed71a1.0006.03\/DOC_1","datePublished":"2013-11-26","publisher":{"@type":"Organization","name":"Publications Office of the European Union"}}],"@id":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation#article"},{"@type":"WebPage","name":"Private Label vs Custom Cosmetic Formulation","url":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation","mainEntity":{"@id":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation#article"},"isPartOf":{"@id":"https:\/\/cosmetic-labs.com\/articles#webpage"},"breadcrumb":{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cosmetic-labs.com\/"},{"@type":"ListItem","position":2,"name":"Blog","item":"https:\/\/cosmetic-labs.com\/articles"},{"@type":"ListItem","position":3,"name":"Private Label vs Custom Cosmetic Formulation","item":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation"}]},"inLanguage":"en-US","@id":"https:\/\/cosmetic-labs.com\/articles\/private-label-vs-custom-formulation#webpage"}]
```